Parkinson's News Today

2 days ago | parkinsonsnewstoday.com | Marisa Wexler

People with Parkinson’s disease have altered levels of certain fat molecules, known as lipids, in their brains, and this may play a role in disease development and progression, a new study from the U.S. reports. The researchers used postmortem brain tissue samples to analyze changes in lipids in 40 Parkinson’s patients and 43 age- and sex-match individuals without the neurodegenerative disease.

3 days ago | parkinsonsnewstoday.com | Andrea Lobo

A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in Canada, to understand how the RAB32 mutation affects the function of neurons and microglia, the resident immune cells in the brain, and increases the risk for Parkinson’s.

5 days ago | parkinsonsnewstoday.com | Andrea Lobo

VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to be safe and well tolerated after nearly one month of daily dosing in a clinical trial involving people with early-stage disease, according to the company. With these results, VTX3232 met the primary goal of the Phase 2a study (NCT06556173), which was conducted in Connecticut, Ventyx announced in a company press release.

1 week ago | parkinsonsnewstoday.com | Steve Bryson

Changes in the bacterial communities in the gut and mouth are associated with cognitive impairment in people with Parkinson’s disease, a study suggests. Some oral bacteria and related virulence factors, such as molecules that help bacteria colonize the body — many of which can trigger a potent inflammatory response — were significantly enriched in the guts of Parkinson’s patients with cognitive impairment.

1 week ago | parkinsonsnewstoday.com | Andrea Lobo

Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage Parkinson’s disease. The decision follows data from two Phase 2 trials showing prasinezumab had potential clinical efficacy at slowing motor symptom progression and reducing motor complications as an add-on to standard treatments. Roche didn’t provide details about its plans for a Phase 3 trial.